Lineage Cell Therapeutics Inc.

Lineage Cell Therapeutics Inc.: (LCTX) is a clinical-stage biotechnology company developing novel cell therapies for unmet medical needs. Lineage’s programs are based on its robust proprietary cell-based therapy platform and associated in-house development and manufacturing capabilities. With this platform Lineage develops and manufactures specialized, terminally differentiated human cells from its pluripotent and progenitor cell starting materials. These differentiated cells are developed to either replace or support cells that are dysfunctional or absent due to degenerative disease or traumatic injury or administered as a means of helping the body mount an effective immune response to cancer. Lineage’s clinical programs are in markets with billion dollar opportunities and include three allogeneic (“off-the-shelf”) product candidates: (i) OpRegen®, a retinal pigment epithelium transplant therapy in Phase 1/2a development for the treatment of dry age-related macular degeneration, a leading cause of blindness in the developed world; (ii) OPC1, an oligodendrocyte progenitor cell therapy in Phase 1/2a development for the treatment of acute spinal cord injuries; and (iii) VAC, an allogeneic dendritic cell therapy platform for immuno-oncology and infectious disease, currently in clinical development for the treatment of non-small cell lung cancer. For more information, please visit http://www.lineagecell.com or follow the Company on Twitter @LineageCell.
Sector/Industry:
Healthcare/Biotechnology
Characteristics:
Based in...
US - Pacific
Clinical Stage
Phase l or ll
Disease Space
Oncology, Ophthalmology
Investement Strategy
Under the Radar
Listing
Public, USA
Market Cap
100MM - 500MM
Therapeutic Modalities
Cell Therapy
Website:
Profiles:
Address:
2173 Salk Avenue
Suite 200
Carlsbad, CA 92008
United States

Company Participants at Lineage Cell Therapeutics Virtual Event

  • Brian Culley, CEO/Interim CFO

Top 10 Holders of Lineage Cell Therapeutics, Inc.

Institution OS (%) Position Mkt Val ($MM) Source Filing Date
Broadwood Capital, Inc. 21.04 34,005,379 97.60 13F 3/31/21
Greenway Partners LP 4.55 6,827,142 19.59 Stakes 3/5/21
The Vanguard Group, Inc. 3.54 5,718,578 16.41 Funds 4/30/21
Vanguard Group, Inc. (Subfiler) 3.39 5,483,936 15.74 13F 3/31/21
Defender Capital LLC 3.06 4,950,720 14.21 13F 3/31/21
BlackRock Institutional Trust Co. NA 1.48 2,395,015 6.87 13F 3/31/21
Prescott General Partners LLC 1.15 1,851,851 5.31 13F 3/31/21
Two Sigma Advisers LP 1.01 1,633,866 4.69 13F 3/31/21
British & American Investment Trust Plc (Invt Mgmt) 1.00 1,499,761 4.30 Funds 12/31/20
Millennium Management LLC 0.88 1,425,776 4.09 13F 3/31/21
Ownership data is sourced through FactSet.

Stock Market Data

Data is being loaded...
Data is being loaded...
Data is being loaded...
Data is being loaded...
Market Data copyright © 2021 QuoteMedia. Data delayed 15 minutes unless otherwise indicated (view delay times for all exchanges). RT=Real-Time, RTB=Real-Time BATS BZX Price/Quote; not sourced from all markets, RTN=Real-Time NASDAQ Basic+ Price/Quote; not sourced from all markets, EOD=End of Day, PD=Previous Day. Market Data powered by QuoteMedia. Terms of Use.